Comparison of replicating and nonreplicating vaccines against SARS-CoV-2
Open Access
- 26 August 2022
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (34) , eabm8563
Abstract
Most gene-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are nonreplicating vectors. They deliver the gene or messenger RNA to the cell to express the spike protein but do not replicate to amplify antigen production. This study tested the utility of replication in a vaccine by comparing replication-defective adenovirus (RD-Ad) and replicating single-cycle adenovirus (SC-Ad) vaccines that express the SARS-CoV-2 spike protein. SC-Ad produced 100 times more spike protein than RD-Ad and generated significantly higher antibodies against the spike protein than RD-Ad after single immunization of Ad-permissive hamsters. SC-Ad–generated antibodies climbed over 14 weeks after single immunization and persisted for more than 10 months. When the hamsters were challenged 10.5 months after single immunization, a single intranasal or intramuscular immunization with SC-Ad-Spike reduced SARS-CoV-2 viral loads and damage in the lungs and preserved body weight better than vaccination with RD-Ad-Spike. This demonstrates the utility of harnessing replication in vaccines to amplify protection against infectious diseases.Keywords
This publication has 34 references indexed in Scilit:
- Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5Journal of Virology, 2017
- Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus VectorsGenes, 2017
- Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine ResponsesJournal of Virology, 2017
- Amplified and Persistent Immune Responses Generated by Single-Cycle Replicating Adenovirus VaccinesJournal of Virology, 2015
- IIIa deleted adenovirus as a single-cycle genome replicating vectorVirology, 2014
- IL-33–Responsive Lineage−CD25+CD44hi Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the LungsThe Journal of Immunology, 2012
- Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agentsVirology, 2009
- Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigenCancer Immunology, Immunotherapy, 2009
- Use of the Syrian Hamster as an Animal Model for Oncolytic Adenovirus Vectors2006
- Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer AntibodiesJournal of Virology, 2005